Pentapeptide compounds are disclosed. The compounds have biological
activity, e.g., cytotoxicity. Prodrugs having targeting groups and pentapeptide
moieities, as well as precursors thereof are also disclosed. For example, precursors
having a reactive linker that can serve as a reaction site for joining to a targeting
agent, e.g., an antibody, as disclosed.
